Hoth Therapeutics (HOTH) and Silo Pharma (SILO) announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs, or VA. The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor, a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions including non-alcoholic fatty liver disease, type 2 diabetes, and central obesity. Deal Highlights include: Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use; 50/50 Joint Venture structure with equal equity and governance participation Lead Indication: Obesity and NAFLD.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics Advances HT-001 for Cancer Treatment
- Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study
- Hoth Therapeutics Regains Nasdaq Compliance on June 18
- Hoth Therapeutics reports results from multi-dose study of HT-KIT
- Hoth Therapeutics granted Japanese patent for HT-KIT platform